This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc., a prominent player in the ophthalmic pharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has rapidly established itself as a leader in developing innovative therapies for eye diseases, particularly glaucoma and retinal disorders. Aerie's core products, including the unique eye drops Rhopressa® and Rocklatan®, are designed to lower intraocular pressure, setting them apart in a competitive market. With a strong focus on research and development, Aerie has achieved significant milestones, including successful product launches and expanding its operational footprint across North America and Europe. The company’s commitment to advancing eye care has positioned it favourably within the industry, earning recognition for its contributions to improving patient outcomes and enhancing the quality of life for those affected by vision-related conditions.
DitchCarbon Score
How does Aerie Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aerie Pharmaceuticals, Inc.'s score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aerie Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is part of a merged entity structure, inheriting emissions data from its parent company, Alcon Inc., at a cascade level of 2. However, no specific emissions figures or reduction targets have been disclosed. Aerie Pharmaceuticals has not publicly committed to any specific climate initiatives or reduction targets, as indicated by the absence of documented reduction initiatives or Science-Based Targets Initiative (SBTi) commitments. The lack of emissions data and climate pledges suggests that Aerie Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly focuses on sustainability, Aerie Pharmaceuticals may benefit from aligning its practices with industry standards and setting measurable targets to reduce its carbon footprint in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - |
| Scope 2 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aerie Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
